<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35236775</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1533-3450</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>Mar</Month>
              <Day>02</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of the American Society of Nephrology : JASN</Title>
          <ISOAbbreviation>J Am Soc Nephrol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Protein Kinase A Downregulation Delays the Development and Progression of Polycystic Kidney Disease.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">ASN.2021081125</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1681/ASN.2021081125</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Upregulation of cAMP-dependent and cAMP-independent PKA signaling is thought to promote cystogenesis in polycystic kidney disease (PKD). PKA-I regulatory subunit RI<i>α</i> is increased in kidneys of orthologous mouse models. Kidney-specific knockout of RI<i>α</i> upregulates PKA activity, induces cystic disease in wild-type mice, and aggravates it in <i>Pkd1</i> <sup>RC/RC</sup> mice.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">PKA-I activation or inhibition was compared with EPAC activation or PKA-II inhibition using <i>Pkd1</i> <sup>RC/RC</sup> metanephric organ cultures. The effect of constitutive PKA (preferentially PKA-I) downregulation <i>in vivo</i> was ascertained by kidney-specific expression of a dominant negative <i>RIαB</i> allele in <i>Pkd1</i> <sup>RC/RC</sup> mice obtained by crossing <i>Prkar1α</i> <sup>R1αB/WT</sup>, <i>Pkd1<sup>RC/RC</sup></i> , and <i>Pkhd1-</i>Cre mice (C57BL/6 background). The effect of pharmacologic PKA inhibition using a novel, selective PRKACA inhibitor (BLU2864) was tested in mIMCD3 3D cultures, metanephric organ cultures, and <i>Pkd1<sup>RC/RC</sup></i> mice on a C57BL/6 × 129S6/Sv F1 background. Mice were sacrificed at 16 weeks of age.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">PKA-I activation promoted and inhibition prevented <i>ex vivo</i> P-Ser133 CREB expression and cystogenesis. EPAC activation or PKA-II inhibition had no or only minor effects. BLU2864 inhibited <i>in vitro</i> mIMCD3 cystogenesis and <i>ex vivo</i> P-Ser133 CREB expression and cystogenesis. Genetic downregulation of PKA activity and BLU2864 directly and/or indirectly inhibited many pro-proliferative pathways and were both protective <i>in vivo</i>. BLU2864 had no detectable on- or off-target adverse effects.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">PKA-I is the main PKA isozyme promoting cystogenesis. Direct PKA inhibition may be an effective strategy to treat PKD and other conditions where PKA signaling is upregulated. By acting directly on PKA, the inhibition may be more effective than or substantially increase the efficacy of treatments that only affect PKA activity by lowering cAMP.</AbstractText>
          <CopyrightInformation>Copyright © 2022 by the American Society of Nephrology.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Xiaofang</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Nephrology and Hypertension and Robert M. and Billie Kelley Pirnie Translational PKD Center, Mayo Clinic, Rochester, Minnesota.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jiang</LastName>
            <ForeName>Li</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Nephrology and Hypertension and Robert M. and Billie Kelley Pirnie Translational PKD Center, Mayo Clinic, Rochester, Minnesota.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Thao</LastName>
            <ForeName>Ka</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Nephrology and Hypertension and Robert M. and Billie Kelley Pirnie Translational PKD Center, Mayo Clinic, Rochester, Minnesota.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sussman</LastName>
            <ForeName>Caroline R</ForeName>
            <Initials>CR</Initials>
            <Identifier Source="ORCID">0000-0003-3965-256X</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Nephrology and Hypertension and Robert M. and Billie Kelley Pirnie Translational PKD Center, Mayo Clinic, Rochester, Minnesota.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>LaBranche</LastName>
            <ForeName>Timothy</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Blueprint Medicines, Cambridge, Massachusetts.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Palmer</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Blueprint Medicines, Cambridge, Massachusetts.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Harris</LastName>
            <ForeName>Peter C</ForeName>
            <Initials>PC</Initials>
            <Identifier Source="ORCID">0000-0002-5304-6593</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Nephrology and Hypertension and Robert M. and Billie Kelley Pirnie Translational PKD Center, Mayo Clinic, Rochester, Minnesota.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>McKnight</LastName>
            <ForeName>G Stanley</ForeName>
            <Initials>GS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, University of Washington, Seattle, Washington.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hoeflich</LastName>
            <ForeName>Klaus P</ForeName>
            <Initials>KP</Initials>
            <AffiliationInfo>
              <Affiliation>Blueprint Medicines, Cambridge, Massachusetts.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schalm</LastName>
            <ForeName>Stefanie</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Blueprint Medicines, Cambridge, Massachusetts.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Torres</LastName>
            <ForeName>Vicente E</ForeName>
            <Initials>VE</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Nephrology and Hypertension and Robert M. and Billie Kelley Pirnie Translational PKD Center, Mayo Clinic, Rochester, Minnesota torres.vicente@mayo.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>02</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Am Soc Nephrol</MedlineTA>
        <NlmUniqueID>9013836</NlmUniqueID>
        <ISSNLinking>1046-6673</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">ADPKD</Keyword>
        <Keyword MajorTopicYN="N">cell signaling</Keyword>
        <Keyword MajorTopicYN="N">cyclic AMP</Keyword>
        <Keyword MajorTopicYN="N">polycystic kidney disease</Keyword>
        <Keyword MajorTopicYN="N">protein kinase A</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>3</Day>
          <Hour>5</Hour>
          <Minute>32</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35236775</ArticleId>
        <ArticleId IdType="doi">10.1681/ASN.2021081125</ArticleId>
        <ArticleId IdType="pii">ASN.2021081125</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
